Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Camrelizumab + Rivoceranib
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Camrelizumab SHR-1210|INCSHR-1210 Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 68 Camrelizumab (SHR-1210) is an antibody that targets PD-1 (PDCD1) and inhibits binding of PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in activation of anti-tumor immune response and decreased tumor growth (PMID: 29358502, PMID: 32623573, PMID: 32581041).
Rivoceranib YN968D1|Apatinib KIT Inhibitor 51 RET Inhibitor 39 SRC Inhibitor 29 VEGFR2 Inhibitor 35 Rivoceranib (apatinib) is an inhibitor of receptor tyrosine kinases, including KDR (VEGFR2), RET, c-KIT, Src, and PDGFRa, which may result in reduced cell proliferation and inhibition of tumor growth (PMID: 21443688, PMID: 32669874).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown stomach cancer not applicable Camrelizumab + Rivoceranib Phase Ib/II Actionable In a Phase Ib trial, combined Camrelizumab (SHR-1210) and Apatinib (YN968D1) treatment resulted in an overall response rate of 17.4% (4/23), a disease control rate of 78.3% (18/23), a median progression-free survival (PFS) of 2.9 months, and an overall survival of 11.4 months in evaluable patients with gastric or gastroesophageal junction cancer (PMID: 30348638; NCT02942329). 30348638
Unknown unknown gastroesophageal junction adenocarcinoma not applicable Camrelizumab + Rivoceranib Phase Ib/II Actionable In a Phase Ib trial, combined Camrelizumab (SHR-1210) and Apatinib (YN968D1) treatment resulted in an overall response rate of 17.4% (4/23), a disease control rate of 78.3% (18/23), a median progression-free survival (PFS) of 2.9 months, and an overall survival of 11.4 months in evaluable patients with gastric or gastroesophageal junction cancer (PMID: 30348638; NCT02942329). 30348638
STK11 mutant lung non-squamous non-small cell carcinoma predicted - sensitive Camrelizumab + Rivoceranib Phase Ib/II Emerging In a Phase Ib/II trial, non-squamous NSCLC patients harboring STK11 and/or KEAP1 mutations (n=14) demonstrated an improved 12-month survival rate (85.1% vs 53.1%; p=0.01), and a trend towards improved objective response rate (42.9% vs 28.1%; p=0.33), disease control rate (92.9% vs 65.6%, p=0.053), and median progression-free survival (9.4 vs 5.3 months; p=0.64) compared to wild-type STK11/KEAP1 patients (n=32) treated with Camrelizumab (SHR-1210) plus Rivoceranib (apatinib) (PMID: 33323401; NCT03083041). 33323401
Unknown unknown lung non-squamous non-small cell carcinoma not applicable Camrelizumab + Rivoceranib Phase Ib/II Actionable In a Phase Ib/II trial, Camrelizumab (SHR-1210) plus Rivoceranib (apatinib) demonstrated safety and resulted in a 30.9% (29/94; one complete, 28 partial responses) objective response rate, 81.9% (77/94) disease control rate, 52.1% (49/94; disease control lasting 24 weeks or more) clinical benefit response rate, median progression-free survival of 5.7 months, and median overall survival of 15.5 months in evaluable patients with non-squamous NSCLC who received prior chemotherapy (PMID: 33323401; NCT03083041). 33323401
Unknown unknown hepatocellular carcinoma not applicable Camrelizumab + Rivoceranib Phase Ib/II Actionable In a Phase Ib trial, combined Camrelizumab (SHR-1210) and Apatinib (YN968D1) treatment resulted in an overall response rate of 50% (8/16), a disease control rate of 93.8% (15/16, stable disease or better), a median progression-free survival (PFS) of 5.8 months, and a 9-month PFS rate of 41.0% in evaluable patients with advanced hepatocellular carcinoma (PMID: 30348638; NCT02942329). 30348638
Unknown unknown hepatocellular carcinoma not applicable Camrelizumab + Rivoceranib Phase II Actionable In a Phase II trial (RESCUE), combined Camrelizumab (SHR-1210) and Rivoceranib (apatinib) treatment resulted in an objective response rate (ORR) of 34.3% (24/70), disease control rate (DCR) of 77.1% (54/70), and median progression-free survival (mPFS) of 5.7 months in previously untreated advanced hepatocellular carcinoma patients, and patients given this combination as second-line therapy demonstrated an ORR of 22.5% (27/120), DCR of 75.8% (91/120), and mPFS of 5.5 months (PMID: 33087333; NCT03463876). 33087333

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries


Additional content available in CKB BOOST